No abstract available.
Humans ; Infant, Newborn* ; Interleukins* ; Sepsis* ; Tumor Necrosis Factor-alpha*

Leiomyoma is a benign solitary tumor which is originated from a smooth muscle cell and grows slowly. It is most commonly found in the uterus and can develop anywhere that smooth muscle is present, including esophagus, lower extremity, stroma of GI tract, and pleura. However, the occurrence of leiomyoma in the hand is so uncommon. We present one case of solid type leiomyoma found in the right 4th finger of a young woman.
Esophagus ; Female ; Fingers ; Gastrointestinal Tract ; Hand ; Humans ; Leiomyoma ; Lower Extremity ; Muscle, Smooth ; Myocytes, Smooth Muscle ; Pleura ; Uterus

No abstract available.
Asthma*

Allogenic peripheral blood stem cell transplantation could be used instead of allogenic bone marrow in treatment of leukemia in children. This 10-year-old female patient with high-risk acute lymphoblastic leukemia received a myeloablative regimen followed by allogenic peripheral blood stem cell transplantation from an HI A-identical sibling donor. Neutrophil recovery to greater than 500/pL occurred at day 11 and platelets recovered to greater than 20,000/pL at day 13. Allogenic peripheral blood stem cell transplantation can be performed safely and may result in a rapid neutrophil and platelet engraftment, without any apparent increased risk of acute graft versus host disease.
Blood Platelets ; Bone Marrow ; Child* ; Female ; Graft vs Host Disease ; Humans ; Leukemia ; Neutrophils ; Peripheral Blood Stem Cell Transplantation* ; Precursor Cell Lymphoblastic Leukemia-Lymphoma* ; Siblings ; Tissue Donors

The aim of this study was to evaluate the risk factors of recurrences after their first febrile convulsions in infants and young children. Dlinical studies were made on 187 cases of febrile convulsions who were admitted to the Department of pediatrics of wallace Memorial Baptist Hospital from March, 1990 to December, 1992. 1) 63 cases of 187 cases had recurrences after their febrile convulsions. Thus, the recurrence rate was 33.7%. 2) The male to female ratio was 2.1:1. And there were no significant differences in recurrence rates between sexes. 3) The recurrence rate was significantly higher in those whose initial febrile convulsions were developed before first 18 months of life than those whose initial convulsions were after 18 months of age (49.5% vs. 12.5%). 4) The time interval from initial attack to recurrence was within 12 months in 80% of cases. 5) Our study revealed that the seizure characteristics of the initial febrile convulsion are not important as predictive factors about the probability of recurrences. 6) Among the total 187 cases, family history were present in 52 cases (27.8%). And there were significantly higher recurrence rates if their families show the same history of febrile convulsion (63.5% vs. 22.2%). 7) The risk of recurrence was much higher in patients whose first febrile history of febrile convulsion at the same time.
Child ; Female ; Humans ; Infant ; Male ; Pediatrics ; Protestantism ; Recurrence ; Risk Factors ; Seizures ; Seizures, Febrile*

No abstract available.
Vasculitis*

This study was performed ta evaluate difference of colposcopic findings between carcinoma in situ and microinvasive carcinoma. From August l, 1988 through November 30,1989, the conixation was undertaken in 138 patients. We compeied colposcpic findings with hiatologic diagnoiis on 1656 seetions. Comparison between the microinvasive carcinorna and the carcinoma in situ groups showed a significant higher incidence of large exoeervtcal lesion size(>3/2 33.9% vs. 1.2%), circumscribved location around external cervical os.(75.0% vs, 51.2%), combined abnormal colposcopic findings(19.6/a vs. 3. 7%) and deep endocervical involvement( >lcm : 23,2% vs. 7. 3%). (P<0.01) Granular area was showed 11% incidence of the worst histologic diagnosis.
Carcinoma in Situ* ; Cervix Uteri* ; Diagnosis ; Female ; Humans ; Incidence

No abstract available.
Abscess*

No abstract available.
Mucopolysaccharidosis II*

No abstract available.
Mucopolysaccharidosis II*